Neuroinflammation in COVID-19 and Depression

Covid19 Clinical Trial

Official title:

Imaging Neuroinflammation in COVID-19 and Persistent Depression With/Without Other Neuropsychiatric Symptoms

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04854785
• Other study ID #: 177/2020
• Status: Active, not recruiting
• Start date: June 14, 2021
• Est. completion date: September 2024

Study information

• Verified date: February 2024
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 2019 (COVID-19) have passed.

Description:

Participants will undergo two positron emission tomography (PET) scans: one [18F]FEPPA scan (for translocator protein (TSPO)) and one [11C]SL25.1188 scan (for monoamine oxidase B (MAO-B)) - as well as one magnetic resonance imaging (MRI) scan. The primary hypotheses are: 1. TSPO total distribution volume (TSPO VT) and MAO-B total distribution volume (MAO-B VT) are greater in the prefrontal cortex (PFC), anterior cingulate cortex (ACC), and hippocampus in COVID-19 with new onset, persistent major depressive episode (MDE) with or without other neuropsychiatric symptoms after recovery from mild respiratory symptoms (DNP-mild). 2. TSPO VT and MAO-B VT are greater in the PFC, ACC, and hippocampus in COVID-19 with new onset, persistent MDE with or without other persistent neuropsychiatric symptoms after recovery from moderate respiratory symptoms (DNP-moderate). Exploratory hypotheses are: 1. Greater TSPO VT and MAO-B VT in the PFC, ACC, and hippocampus will be positively associated with severity of MDE symptoms and poorer performance on cognitive tasks. 2. TSPO VT and MAO-B VT will be positively correlated in the PFC, ACC and hippocampus in COVID-DNP.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 120
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age 18 to 80
• Diagnosis of COVID-19
• Recovered from mild or moderate COVID-19 symptoms. Mild is defined as no evidence of pneumonia or hypoxia. Moderate is defined as presence of clinical symptoms of pneumonia but not severe enough to require ongoing use of supplementary oxygen.
• Recovered from physical COVID-19 symptoms including cough, shortness of breath, fever, chills, or gastrointestinal upset for at least 4 weeks
• New onset major depressive episode (MDE) within 3 months after COVID-19, as verified by the Research Version of Structured Clinical Interview for DSM 5 (SCID-5-RV)
• High-affinity-binder (HAB) or mixed-affinity-binder (MAB) genotype for rs6971 polymorphism, based on saliva genetic testing

Exclusion Criteria:

• Lifetime history of an autoimmune disease
• Lifetime history of a neurological disease, excluding migraine
• Lifetime diagnosis of Antisocial or Borderline Personality disorder
• Lifetime history of psychotic symptoms prior to COVID-19
• Lifetime diagnosis of Substance of Alcohol Use Disorder
• Use of street drugs, including marijuana, in the past two months
• Presence of cigarette smoking in the past two months
• Positive urine drug or cotinine screen at any timepoint during the study
• Currently pregnant
• Currently breastfeeding
• Use of aspirin or ibuprofen within the past 2 weeks
• Use of any other anti-inflammatory medication or MAO-B inhibitors within the past 4 weeks
• Use of herbal remedies in the past month
• Presence of metal implant, object or electrical devices that are contraindicated for MRI
• Current disorders of coagulation, blood or ongoing use of anticoagulant medication
• Claustrophobia
• Weight over 400lbs and height over 7ft
• History of undergoing a number of PET scans that will lead participants to exceed the annual (20mSv) / lifetime (8 PET scans) radiation by completing this study
• Current participation in another research study

Related Conditions & MeSH terms

• COVID-19
• Covid19
• Major Depressive Episode

Intervention

Other:
• [18F]FEPPA PET scan
One [18F]FEPPA PET for TSPO VT, and one MRI scan
• [11C]SL25.1188 PET scan
One [11C]SL25.1188 PET scan for MAO-B VT, and one MRI scan

Locations

Country	Name	City	State
Canada	Centre for Addiction and Mental Health	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Translocator protein total distribution volume in prefrontal cortex, anterior cingulate cortex, and hippocampus	PET scan measures in DNP-mild and DNP-moderate compared to healthy controls	within 3 to 4 weeks after initiation of screening
Primary	Monoamine oxidase B total distribution volume in prefrontal cortex, anterior cingulate cortex, and hippocampus	PET scan measures in DNP-mild and DNP-moderate compared to healthy controls	within 3 to 4 weeks after initiation of screening